PolyTherics, Pro Bono Bio deal

PolyTherics and Pro Bono expanded a 2009 agreement for Pro Bono to develop a pegylated, longer-acting version of Factor IX using PolyTherics' TheraPEG technology. Under the expanded deal, the parties will now develop a Factor VIIa product using TheraPEG. PolyTherics is eligible for milestones and royalties for both products. The pegylated Factor VIIa and IX have completed preclinical testing. Pro Bono expects to start clinical testing in 18-24 months. PolyTherics received an undisclosed milestone payment in April for transferring its TheraPEG pegylation process for the Factor IX to Pro Bono Bio for further development. ...